Current Headlines

  1. Ionetix Announces Approval Of Abbreviated New Drug Application For Gallium Ga-68 Gozetotide (PSMA-11) 5/26/2026

    Ionetix Corporation (“Ionetix”), a leading particle accelerator company focused on the medical, materials testing and nuclear energy space, announced today that the Federal Drug Administration (FDA) has approved its Abbreviated New Drug Application for Gallium Ga-68 gozetotide.

  2. Deepening Focus On Autoimmune Diseases, Empowering AI-Driven Drug Discovery 5/26/2026

    The global population affected by autoimmune diseases continues to grow steadily, driving strong demand for innovative therapeutics and supporting robust expansion of the preclinical CRO market.

  3. Ginkgo Datapoints, Tangible Scientific, And Inductive Bio Launch ADME-One™: A High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier In Drug Discovery 5/26/2026

    Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™, a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio.

  4. Biocytogen Launches AI-Powered RenSuper Platform And Industry-First Fully Automated Antibody Discovery Infrastructure 5/26/2026

    Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production.

  5. Curi Bio Launches The Curiverse At MPS 2026: The Industry's First Closed-Loop Ecosystem For Industrial-Scale, Human-Relevant Drug Discovery 5/26/2026

    Curi Bio, a global leader in functional human biology, today unveiled the Curiverse at the Microphysiological Systems World Summit (MPS) 2026, the industry’s first closed-loop ecosystem unifying assay-ready iPSC-derived cells, automated high-throughput systems, and cloud-based data analytics for industrial-scale 3D human drug discovery.

  6. Dicot Pharma Submits An IND Application To The FDA 5/25/2026

    Dicot Pharma AB announces that the company has submitted an IND application (Investigational New Drug Application) to the US Food and Drug Administration, FDA, ahead of the planned phase 2b study of the drug candidate LIB-01, developed for erectile dysfunction.

  7. Stellora.AI Advances Quantum Flow To Support Healthcare, Drug Discovery, And Disease Research 5/25/2026

    Stellora.AI, a deep-tech artificial intelligence startup developing advanced agentic AI and quantum workflow technology, today announced the continued advancement of Stellora.AI Quantum Flow, a core part of its broader mission to support healthcare innovation, drug discovery, and research into complex diseases.

  8. Lupin Receives China Approval For Oseltamivir Phosphate Oral Suspension 5/22/2026

    Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that China's National Medical Products Administration has approved its Abbreviated New Drug Application for Oseltamivir Phosphate, in partnership with Yabao Pharmaceuticals, a leader in China's paediatric medicine market.

  9. Concept Life Sciences Partners With OpenBench To Deliver Success-Based Drug Discovery Services For Early-Stage Biotech 5/21/2026

    Concept Life Sciences, a leading global contract research organization (CRO) with expertise in integrated drug discovery and development, and OpenBench, a pioneer of success-based AI hit discovery, today announced a strategic partnership to accelerate hit identification for biotech companies through a fee-for-success model.

  10. Incyte And Genesis Expand Molecular AI Collaboration To Accelerate Drug Discovery 5/20/2026

    Incyte and Genesis Molecular AI today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte.